Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Aztreonam Lysinate for Inhalation in Cystic Fibrosis (AIR-CF3)
NCT00128492Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Aug 2005
- Primary completion
- Nov 2008
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of aztreonam in cystic fibrosis (CF), sponsored by Gilead Sciences. Started Aug 2005; status: completed.
02
Drugs
aztreonam
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT00128492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00128492.